Suven Life Sciences Limited (SUVEN.BO)
INR 142.95
(-0.56%)
INR 142.95
(-0.56%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -992.78 Million INR | -7.32% |
| 2022 | -1.11 Billion INR | 1.47% |
| 2021 | -1.16 Billion INR | -67.27% |
| 2020 | -721.87 Million INR | 29.22% |
| 2019 | -1.01 Billion INR | -1849.98% |
| 2018 | 162.66 Million INR | -102.56% |
| 2017 | 2.24 Billion INR | 52.08% |
| 2016 | 1.56 Billion INR | 22.99% |
| 2015 | 1.27 Billion INR | -38.94% |
| 2014 | 1.81 Billion INR | -18.59% |
| 2013 | 2.21 Billion INR | 295.12% |
| 2012 | 557.83 Million INR | 113.48% |
| 2011 | 261.3 Million INR | 118.76% |
| 2010 | -1.39 Billion INR | -936.24% |
| 2009 | 163.43 Million INR | -15.14% |
| 2008 | 189.88 Million INR | 14.86% |
| 2007 | 175.35 Million INR | -0.11% |
| 2006 | 171.06 Million INR | 29.29% |
| 2005 | 125.18 Million INR | 26.66% |
| 2004 | 107.24 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -481.73 Million INR | -81.58% |
| 2024 Q1 | -305.38 Million INR | -2.02% |
| 2023 FY | - INR | -7.32% |
| 2023 Q4 | -302.87 Million INR | 24.52% |
| 2023 Q1 | -223.74 Million INR | 19.38% |
| 2023 Q3 | -401.26 Million INR | -118.45% |
| 2023 Q2 | -183.68 Million INR | 17.91% |
| 2022 Q3 | -493.8 Million INR | -129.76% |
| 2022 FY | - INR | 1.47% |
| 2022 Q2 | -214.92 Million INR | -4.11% |
| 2022 Q4 | -277.55 Million INR | 43.79% |
| 2022 Q1 | -206.43 Million INR | 12.46% |
| 2021 Q1 | -417.37 Million INR | -104.59% |
| 2021 FY | - INR | -67.27% |
| 2021 Q4 | -235.81 Million INR | 27.08% |
| 2021 Q3 | -323.38 Million INR | -19.27% |
| 2021 Q2 | -271.14 Million INR | 35.04% |
| 2020 Q1 | -116.96 Million INR | 47.17% |
| 2020 Q2 | -153.15 Million INR | -30.95% |
| 2020 Q3 | -250.16 Million INR | -63.34% |
| 2020 Q4 | -204 Million INR | 18.45% |
| 2020 FY | - INR | 29.22% |
| 2019 Q4 | -221.39 Million INR | -1.49% |
| 2019 FY | - INR | -1849.98% |
| 2019 Q3 | -218.14 Million INR | -16.65% |
| 2019 Q1 | -390.91 Million INR | -130.07% |
| 2019 Q2 | -187 Million INR | 52.16% |
| 2018 Q4 | 1.3 Billion INR | 1098.26% |
| 2018 Q1 | 535.43 Million INR | 0.0% |
| 2018 Q3 | -130.23 Million INR | -177.24% |
| 2018 Q2 | 168.6 Million INR | -68.51% |
| 2018 FY | - INR | -102.56% |
| 2017 FY | - INR | 52.08% |
| 2016 FY | - INR | 22.99% |
| 2016 Q4 | 531.04 Million INR | 0.0% |
| 2015 Q3 | 286.05 Million INR | -21.67% |
| 2015 Q4 | 531.96 Million INR | 85.97% |
| 2015 FY | - INR | -38.94% |
| 2015 Q2 | 365.2 Million INR | 21.27% |
| 2015 Q1 | 301.14 Million INR | 326.77% |
| 2014 Q2 | 373.21 Million INR | -32.75% |
| 2014 Q1 | 554.96 Million INR | 21.69% |
| 2014 FY | - INR | -18.59% |
| 2014 Q4 | 70.56 Million INR | -85.51% |
| 2014 Q3 | 486.93 Million INR | 30.47% |
| 2013 Q1 | 461.87 Million INR | 252.8% |
| 2013 Q4 | 456.05 Million INR | -18.17% |
| 2013 Q3 | 557.34 Million INR | -22.08% |
| 2013 FY | - INR | 295.12% |
| 2013 Q2 | 715.26 Million INR | 54.86% |
| 2012 Q3 | 152.34 Million INR | 38.53% |
| 2012 Q4 | 130.91 Million INR | -14.07% |
| 2012 FY | - INR | 113.48% |
| 2012 Q1 | 138.61 Million INR | 0.0% |
| 2012 Q2 | 109.97 Million INR | -20.66% |
| 2011 FY | - INR | 118.76% |
| 2010 FY | - INR | -936.24% |
| 2009 FY | - INR | -15.14% |
| 2008 FY | - INR | 14.86% |
| 2007 FY | - INR | -0.11% |
| 2006 FY | - INR | 29.29% |
| 2005 FY | - INR | 26.66% |
| 2004 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ajanta Pharma Limited | 12.56 Billion INR | 107.901% |
| Amrutanjan Health Care Limited | 682.53 Million INR | 245.454% |
| Sigachi Industries Limited | 883.39 Million INR | 212.382% |
| Bal Pharma Limited | 345.59 Million INR | 387.269% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 114.469% |
| Medico Remedies Limited | 150.37 Million INR | 760.19% |
| Lasa Supergenerics Limited | -65.08 Million INR | -1425.476% |
| Venus Remedies Limited | 711.8 Million INR | 239.474% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 73.393% |
| Alpa Laboratories Limited | 86.12 Million INR | 1252.693% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 163.486% |
| Shilpa Medicare Limited | 2.58 Billion INR | 138.361% |
| Aarti Drugs Limited | 3.24 Billion INR | 130.56% |
| Lupin Limited | 36.96 Billion INR | 102.685% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 101.607% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 101.766% |
| Windlas Biotech Limited | 781.72 Million INR | 226.999% |
| Eris Lifesciences Limited | 6.98 Billion INR | 114.21% |
| Valiant Laboratories Limited | 12.73 Million INR | 7893.233% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 110.635% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 64.819% |
| Ipca Laboratories Limited | 13.29 Billion INR | 107.465% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 167.124% |
| Achyut Healthcare Limited | 524 Thousand INR | 189561.832% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 100.718% |
| Bajaj HealthCare Limited | 444.51 Million INR | 323.34% |
| RPG Life Sciences Limited | 1.28 Billion INR | 177.47% |
| Mankind Pharma Limited | 28.09 Billion INR | 103.534% |
| Laurus Labs Limited | 8 Billion INR | 112.4% |
| Piramal Pharma Limited | 13.05 Billion INR | 107.604% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 330.731% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 102.836% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 110.323% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 108.752% |
| Unichem Laboratories Limited | 742.35 Million INR | 233.734% |
| Sequent Scientific Limited | 549.8 Million INR | 280.571% |
| Novartis India Limited | 1.26 Billion INR | 178.215% |
| Wanbury Limited | 985.49 Million INR | 200.74% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 121.226% |
| Wockhardt Limited | 1.08 Billion INR | 191.924% |
| Themis Medicare Limited | 562.6 Million INR | 276.461% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 406.925% |
| Jubilant Pharmova Limited | 8 Billion INR | 112.4% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 114.466% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 101.125% |
| Divi's Laboratories Limited | 25.43 Billion INR | 103.904% |
| NATCO Pharma Limited | 18.79 Billion INR | 105.282% |
| Gufic Biosciences Limited | 1.48 Billion INR | 167.058% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 138.087% |
| Ind-Swift Limited | 1.06 Billion INR | 193.213% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 132.935% |
| FDC Limited | 4.4 Billion INR | 122.555% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | -1100.068% |
| Granules India Limited | 8.6 Billion INR | 111.539% |
| Medicamen Biotech Limited | 245.66 Million INR | 504.128% |
| Alkem Laboratories Limited | 24.19 Billion INR | 104.103% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 142.124% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | 7700.521% |
| Brooks Laboratories Limited | 41.72 Million INR | 2479.17% |
| Megasoft Limited | 284.73 Million INR | 448.673% |
| ZIM Laboratories Limited | 462.09 Million INR | 314.842% |
| Strides Pharma Science Limited | 3.76 Billion INR | 126.371% |
| Neuland Laboratories Limited | 4.74 Billion INR | 120.909% |
| Morepen Laboratories Limited | 1.72 Billion INR | 157.521% |
| Hikal Limited | 2.69 Billion INR | 136.876% |
| Indoco Remedies Limited | 2.64 Billion INR | 137.505% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 125.395% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | 445.405% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | 667.478% |
| Hester Biosciences Limited | 539.47 Million INR | 284.029% |